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 A STUDY OF SERUM LEVELS OF FIBRINOGEN IN SMOKERS AND ITS 
CORRELATION WITH TYPE , AMOUNT AND DURATION OF 
SMOKING:  
Abstract 
Background: According to many studies, serum levels of fibrinogen is found to 
be higher in smokers than in non smokers.This may contribute to increase in the 
incidence of myocardial infarction and cerebro vascular accidents in future. 
Aims: To find out the levels of serum fibrinogen in smokers and non smokers 
and compare the levels of serum fibrinogen in smokers according to their type, 
amount and duration of smoking.  
Materials and methods: 100 patients and their attenders , who did not fit into 
the exclusion criteria were taken as the study population. The control group had 
50participants. The serum fibrionogen levels were measured using the clauss  
method. 
Results: Out of the 100cases smokers and 50 non smokers , smokers have 
higher levels of serum fibrinogen than non smokers. The levels of serum 
fibrinogen were also higher in persons who smoked for many years and higher 
pack years.  
 
 Conclusion: In this study, smokers have higher levels of serum fibrinogen than 
non smokers. The levels of serum fibrinogen were also higher in persons who 
smoked for many years and higher pack years. The incidence of                    
thrombo embolic episodes were also more in smokers. 
 
Key words: serum fibrinogen , smoking , cigarette smoking , myocardial 
infarction. 
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STUDY ON SERUM LEVELS OF SERUM FIBRINOGEN ON SMOKERS: 
 
 
INTRODUCTION: 
 
 
Smoking produces a state of chronic inflammation which 
 
                    is mainly due to increased levels of free radicles. Free  
 
radicles  produces an oxidative stress thisdamages mainly 
 
 the cardio vascular system. blood vessels and central  
 
nervous system are also affected. The cell damage  
 
anddamage recycling process are done by antioxidants. In  
 
smokers the antioxidants levels are reduced which  
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causesimproper cell repair and damage. Smoking  causes  
 
narrowing of airways which also affects  pulmonary  
 
function test. cigarettes also contain  carcinogens . This  
 
predisposes  them to many  cancers. Smoking is also  
 
associated with low levels of high density lipoprotein.  
 
This increases the risk of atherosclerosis. Smoking is a  
 
mediator of inflammation . Therefore it increases the  
 
levels of acute phase reactants. One among them is  
 
fibrinogen. Fibrinogen is synthesized by liver. Apart from  
 
its major role in coagulation cascade it is also produced in  
 
various inflammatory conditions as an acute phase  
 
reactant. Smoking as a main cause for chronic  
 
inflammation it increases the levels of serum fibrinogen.  
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Increasedfibrinogen keeps the blood in a hyper coagulated  
 
 state. Since hyper coagulation causes arterial and venous  
 
thrombosis increased fibrinogen is associated with major  
 
cerebro and cardio vascular events. Our aim of study is to  
 
measure the levels of serum fibrinogen among the  
 
smokers and comparing the level of fibrinogen in smokers  
 
based on their duration , amount  and type of smoking. 
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AIM: 
 To measure the level of serum fibrinogen in 
smokers. 
 To study the relationship between duration of 
smoking and the level of serum fibrinogen. 
 To study the relationship between the pack 
years and the levels of  serum fibrinogen. 
 To study the relationship between the type of 
smoking and the levels of serum fibrinogen. 
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REVIEW OF LITERATURE: 
 
Fibrinogen: 
Fibrinogen is one of the clotting factors synthesized by  
liver. It plays important role in 
 
i. Coagulation pathway. 
 
ii. As an acute phase reactant plays an important role  
 
in inflammatory pathway.Increased levels of serum  
 
fibrinogen is associated with increased risk of  cardio  
 
vascular , cerebro  vascular accidents and other thrombo  
 
embolic complications. 
 
Plasma levels of fibrinogen is increased by 
 
i. Age 
 
ii. Diabetes 
 
iii. Hyperlipidemia 
 
iv. Hypertension 
 
v. Smoking 
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vi. Low density lipoprotein 
 
vii. Post menopausal state 
 
viii. Body mass index 
 
ix. Leukocytosis 
 
Plasma levels of fibrinoged is decreased by 
 
 
i. Moderate consumption of alcohol 
 
ii. Increased levels of HDL 
 
iii. Hormone replacement therapy 
 
Fibrinogen is a glycoprotein . it is synthesized by liver
[3]
.  
 
Its molecular weight is  340 Kda
[2].
 Half life of fibrinogen 
 
 is 100 hrs. normal serum levels of fibrinogen is 200 to  
 
400 mgs/ dl. Its structure is composed of three pairs of   
 
three  peptide chains . 
 
i. Alpha chains  
 
ii. Beta chains and 
 
iii. Gamma chains 
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The chains are non identical. The chains are connected to 
 
 each other by disulfide linkages.Fibrinogen is the  
 
precursor of fibrin . fibrin is essential for clotting. 
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Fibrinogen is essential in the pathophysiology of 
 
i. Inflammation 
 
ii. Coagulation 
 
iii. Thrombus formation[4] 
 
Fibrinogen and inflammation: 
 
Fibrinogen  promotes the binding of leukocytes to  
 
endothelium and also activation of leukocytes. It is mainly  
 
through binding with receptors present in leukocytes  
 
and endothelial cell. By binding with  ICAM-1 it  
 
promotes the binding of neutrophils and monocytes with  
 
endothelial cells. Fibrinogen causes activation of  
 
leukocytes by increasing the intra cellular levels of  
 
calcium and also by increasing the levels of neutrophil  
 
activation markers.
[5][6] 
As a result of this there is  
 
increased phagocytosis and antibody mediated  
 
cytotoxicity.  Fibrinogen also causes cell to cell  
 
interaction and  also cell to matrix interaction. 
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Fibrinogen and thrombosis: 
 
Fibrinogen binds with platlets surface receptors gpiib –  
iiia  and promotes platlets aggregation fibrinogen  plays  
an important role in coagulation pathway by participating  
 in both intrinsic and extrinsic pathway. When there is  
damage to endothelial cells and causes the release of  
tissue thromboplastin which inturnactivates  factor vii  
which causes the activation of extrinsic pathway. When   
blood comes into contact with foreign body activation of  
factor xii to xii a which causesthe activation of intrinsic  
pathway. Both pathways merges into common pathway  
which causes the activation of conversion of 
 
 thrombinogen to thrombin.Thrombin converts fibrinogen  
 
into fibrin which is the final step in coagulation
[7]
.  
 
Finally activation of factor xiii causes the stabilization of 
clot. 
 
Fibrinogen and atherogenesis: 
 
Fibrinogen plays dual role in atherogenesis. It causes both  
 
formation of plaques and also growth of plaques. 
 
 Fibrinogen is seen either in the surface of the plaque cap  
 
or within the cap or seen evenly distributed throughout the  
 
atheromatous plaque. Inside intima Fibrinogen  binds with  
 
fibronectin 
[8][9]
. 
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Fibronectin promotes cell migration and adhesion inside  
 
intima.  Fibrin degradation products also promotes cell  
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proliferation and mitogenesis. Inside stable plaque  
 
fibrinogen binds  tightly with LDL and helps in plaque  
 
extension.As a result of these process there is  progression  
 
of atherogenesis 
Determinants of plasma fibrinogen levels: 
 
The level of serum fibrinogen is determined by 2 factors. 
 
i. Genetic 
 
ii. Environmental 
 
Genetic: 
 
Synthesis of fibrinogen is under genetic control.The long 
 
 arm of chromosome 4 synthesises the three chains.The  
 
direction of transcription of beta gene is opposite to that 
 
 of alpha and gamma gene.Variation in the locus of  
 
fibrinogen locus leads to variation in plasma fibrinogen  
 
levels.The synthesis of beta chain is the rate limiting step  
 
in the synthesis of plasma fibrinogen.Recently various 
 
 polymorphisms have been found that affect the plasma  
 
fibrinogen value.These polymorphisms can be identified  
 
by Restriction Fragment Length Polymorphism(RFLP) 
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and also by Single Stranded Conformation  
 
Polymorphism (SSCP). One of the strongest genetic  
 
variations associated with increased plasma fibrinogen is  
 
the 455G/A mutation in the promoter region of fibrinogen  
 
gene. One study suggests that B1B1 genotype  
is associated with fibrinogen level of 2.74g/dl whereas  
B2B2 phenotype is associated with serum fibrinogen level  
of 3.69g/dl
[10][11]. This level is considered as the cut off  
level for the development of ischemic heart disease. 
 
Environmental factors: 
 
Serum fibrinogen value is influenced by many  
 
environmental factors and also patient’s lifestyle. 
 
i. Smoking 
 
Smoking  is associated with increase in the level of serum 
 
fibrinogen value.The effect is mainly dose dependent.   
 
There is inverse relationship between serum fibrinogen  
 
value and time  since stopping the habit of smoking
[12]
. 
 
 
ALCOHOL: 
 
Moderate consumption of alcohol is associated with lower  
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levels of serum fibrinogen. 
 
Factors associated with higher levels of fibrinogen: 
 Female sex 
 
 Black race 
 
 Increase in age 
 
 Obesity 
 
 Elevated cholesterol 
 
 Smoking 
 
 Physical inactivity 
 
 Oral contraceptives 
 
 Menopause  
 
 Stress 
  
 Low socioeconomic status 
 
Factors associated with lower levels of fibrinogen: 
 Male sex 
 
 Young age 
 
 Stop the habit of smoking 
 
 Regular aerobic exercises 
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 Reduction of weight 
 
 
 Mediocre consumption of alcohol 
 
 Hormone replacement therapy. 
 
Interventions to reduce serum fibrinogen levels: 
 
Beneficial: 
 Cessation  of smoking 
 
 Drugs: fibrates 
 
May be beneficial: 
 
 Moderate consumption of alcohol 
 
 Weight loss 
 
 Lowering of blood pressure. 
 
Not  beneficial: 
 
 Statins 
 
Gender: 
 
Studies  shown that serum fibrinogen is higher in females  
 
than in males.This value is constant irrespective of the age 
                                                                                                                   
pregnancy and use of oral contraceptives 
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Age: 
 
Serum fibrinogen value increases as the age  
 
advances
[13][14]
. This is mainly due to slower  
 
rate of disposal of fibrinogen than the increased  
 
production.Body mass index and body habitus: 
 
Serum fibrinogen increases with increase in body weight  
 
Waist circumference , hip circumference and waist hip  
 
ratio.Serum fibrinogen levels in persons with BMI >  
 
30kg/m2 is higher when compared to persons with BMI  
 
<25 kg/m2. Serum fibrinogen value decreases after  
 
surgicalcorrection of obesity after 6 months
[15]
 
 
Metabolic syndrome: 
 
This is charerterised by the presence of 3 or more of the 
following. 
 
i. High-density lipoprotein-cholesterol < 1.13 mmol/l 
 
ii. Triglycerides  >1.80 mmol/l; 
 
 
iii. Glucose  >5.5 mmol/l; 
 
iv. Diastolic blood pressure _90mm Hg. 
 
Serum fibrionogen increases with increase in any one of  
 
the above  parameters. 
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Acute exercise: 
 
Acute exercise has no effect on serum fibrinogen value.  
 
But in patients with vascular diseases acute exercise  
 
increases the levels of serum fibrinogen
[16]
. 
 
Regular exercise: 
 
Regular exercise reduces the levels of serum fibrinogen . 
 
 One study proved that 4 weeks of regular exercise lowers 
 
 the levels of serum fibrinogen
[17]
.Serum fibrinogen values  
 
returns to normal values  after resumption of sedentary 
 
 activities. Men and women who have higher levels of  
 
activity has lower levels of fibrinogen. 
 
Seasonal variation: 
 
Fibrinogen value changes with season. Its value rises in  
 
persons during winter season and decreases during  
 
summer season.
[18][19][20][21][22] 
 
 
Vitamin C and infection: 
 
Decreased levels of body vitamin c is associated with  
 
increased levels of serum fibrinogen.Upper respiratory  
 
tract infection  is associated with increased levels of  
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serum fibrinogen. Chlamydia and helicobacter infections 
 
 are associated with increased incidence of coronary heart  
 
disease. Whether their effect is mediated through  
 
increased levels of fibrinogen is unknown. 
 
Socio economic status: 
 
Socio economic status is inversely related to serum levels 
of fibrinogen. 
 
Hormonal status: 
 
Post menopausal status is associated with increased serum  
 
levels of fibrinogen
[23]
 . Oral contraceptive usage is  
 
associated with  increased serum levels of serum  
 
fibrinogen.Hormone replacement treatment in post  
 
menopausal women is associated with lower levels of  
 
serum fibrinogen
24
. 
 
Alcohol: 
 
There is U shaped association between serum levels of  
 
fibrinogen and alcohol consumption
[25]
. Moderate  
 
consumption of alcohol is associated with lower levels of  
 
serum fibrionogen value but consumption of more than  
 
60 g/ day is associated with higher fibrinogen levels. 
 
Higher consumption is associated with high bp and  
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development of atrial fibrillation which increases the  
 
levels of fibrinogen. 
 
 
Smoking: 
 
Smoking is the most dangerous health hazard. Smoking  
 
took part in the entire process of atherosclerosis from 
 
 endothelial dysfunction to thrombogenesis both active  
 
and passive smoking contributes to the pathogenesis of  
 
harmful effects. Even smokeless cigarettes can also cause 
 
 damage. It is mainly contributed to the oxidative stress  
 
produced by the toxic substances present in the smoke. 
 
Smoking is in the form of    1. cigarettes  
                                       
                                             2.  bedis  
 
                                             3. cigars 
 
 
                                             4.hookahs 
 
                                             5. vaporizers  
 
                                             6. bongs. 
 
Tobacco smoking is the most common type of smoking .  
 
Next is cannabis smoking. 
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Smoke: 
 
Smoke is composed of 2 phases. 
 
i. Tar phase 
 
ii. Gas phase[26] 
 
Tar phase is the particulate matter present in smoke which  
 
gets trapped while passing through the Cambridge gas  
 
filter.Gas phase is the substance that passes through the 
 
 gas filter.Tar phase consists of  >10
17
 free radicals/g,  and  
 
the gas phase consists of  >10
15
 free radicals/puff . The  
 
free radicles present in tar phase is long living (hours to  
 
months) while the free radicles present in gas phase is  
 
short living (few seconds). 
 
Smoke is also of 2 types. 
 
 
i. Main stream stroke 
 
ii. Side stream stroke.27 
 
The smoke that enters smokers mouth through the end of  
 
the cigarette is called main stream stroke
[29].
 The smoke  
 
that emerges from the burning end of  the cigarette is  
 
called as side stream stroke
[28]
. Mainstream stroke  
 
contains gas 90% and tar particles 10% Passive smoking  
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is mainly composed of side stream smoke 85% 
 
Side stream smoke contains more toxic substances than  
 
main stream smoke.Smoking  leads to atherosclerosis by  
 
many ways. The outcome of atherosclerosis may be in 
 
 the form of unstable angina , acute coronary syndrome 
 
 sudden death and stroke. It also involves aorta and  
 
peripheral vessels leading to intermittent claudication and  
 
aortic aneurysm. Smoking promotes atherosclerosis 
 
by 3 main ways. 
 
 Inflammation 
 
 Vasomotor dysfunction 
 
 Modification of lipid levels 
 
Vasomotor dysfunction: 
 
The earliest way by which smoking produces  
 
atherosclerosis is by causing impairment in vasodilation. 
 
 This is seen in both active as well as in passive smoking. 
 
Cigarette smoking impairs endothelium dependend  
 
vasodilation in both macro vascular and micro vascular 
 
 circulation. Nitric oxide is the main vasodilatory 
 
 substance present in 
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our body. Smoking decreases the availability of nitric  
 
oxide to endothelial cells besides vasodilation smoking 
 
 also plays an important role in regulation of  
 
inflammation , leukocyte adhesion , thrombosis and  
 
platlet activation. 
 
Smoking and inflammation: 
 
Inflammation is the second step in atherogenesis.  
 
Smoking  provokes inflammation by causing increased  
 
expression of cell adhesion  molecules on the surface of  
 
both endothelial cells and leukocytes mainly ICAM 1  
 
andVCAM 1.  Smoking also increases leukocyte count  
and also promotes cell to cell interaction. Thus smoking  
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adds fuel to the fire of inflammation. 
 
Smoking and lipid profile: 
 
Smoking promotes atherosclerosis by altering lipid 
 
 profile. It increases triglycerides , low density lipoprotein 
 
 but lowers high density lipoprotein. These effects are 
 
 mainly due to insulin resistance. Smoking promotes 
 
 oxidation of LDL and also causes the synthesis of auto 
 
 antiobodies to LDL. Endothelial cells identified from 
 
 smokers have higher levels of oxidized LDL. Smokers 
 
 have lower levels of paroxanase an enzyme involved in 
  
protecting the oxidization of LDL. 
 
 
 
Smoking and genetic predisposition: 
 
Genetic predisposition also affects the rate of  
 
development of atherogenesis in individuals with  
 
smoking.  Polymorphism of CYP1A1 or endothelial nitric 
 
oxide synthetase 4 polymorphism alters the development 
 
 of atherogenesis. 
 
 
 
Smoking and thrombosis: 
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Smoking promotes thrombosis formation leading to acute  
 
myocardial infarction. Main mechanism is by plaque  
 
rupture and formation of thrombus on plaque. It also  
 
causes vasospasm there by causing prinzmetal angina.  
 
By contrast cessation of smoking reduces the risk of  
 
thrombosis. At the end of 5 years ex smokers have  
 
same risk as that of non smokers. A study by sergeant, 
 
 shepard , glantz at 52nd annual American conference of  
 
cardiology confirmed this. Smoking is the most   
 
preventable common cause of mortality and morbidity  
 
all over the world.  Smoking is responsible for 4,43,000  
 
deaths all over world per year.This includes those who  
 
are affected by second hand smoking like the babies who 
 
are affected by maternal smoking. Cigarette smoking  
 
 contains more than 7000chemicals out of which 69 are  
 
found to be carcinogens. The most common cause 
 
of death due to smoking is attributed to lung cancer and  
 
next one to COPD. Age is the most important risk factor  
 
for the developmentof coronary heart disease. Apart from   
 
age smoking is the most common cause. Among the  
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persons with smoking habit ischemic heart disease is the  
 
leading cause of mortality. The prevalence of smoking is  
 
very common in developing countries. Habit of smoking 
 
 is decreased in developed countries. China is the country  
 
which has the largest number of smokers. Second one is  
 
India. Smoking is responsible for the death of more than  
 
two billion per year.  Even among the non smokers  
 
passive smoking is responsible for the most common  
 
cause of mortality from ischemic heart disease.  
 
Smoking’s adverse effects depends upon many features. 
 
 Amount of smoking ,type of smoking , duration .  
 
smokers have high risk of developing many problems 
 
 compared to nonsmokers. Among smokers  light smokers 
 
 have less risk compared to heavy smokers.  Risks  
 
increases with the quantity of smoking daily.  Smoking  
 
was initially very prevalent among men . but nowadays  
 
its prevalence increased among women. If a women takes 
 
 oral contraceptives along with smoking she had  
 
higher risk compared to women who is not taking oral  
 
contraceptive pills. Smoking causes rise in blood pressure.  
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It increases both systolic and diastolic blood pressure. It  
 
increases sympathetic tone. It promotes the formation of  
 
atherosclerosis . it causes the risk of atherosclerosis  
 
rupture. It increases the formation of thrombosis and leads 
 
 to reduced blood flow to myocardium. This leads to the 
 
 adverse cardio vascular  side effects. It increases the 
 
 oxidation of low density lipoproteins. It reduces the 
 
 synthesis of nitric oxide . nitric oxide is also called as 
 
 endothelium derived relaxing factor. It increases tissue 
 
 type plasminogen activator. It increases the tissue 
 
 pathway factor inhibitor.  Smoking increases  
 
fibrionogen. Smoking increases homocysteine.  It  
 
increases platlet aggregation.smoking increases the risk 
  
of coronary spasm. It is associated with increased risk of  
 
 ventricular arrhythmias. It increases insulin resistance. 
 
 Stopping smoking is the most important  protocol in the 
 
 treatment of coronary  heart disease. Cigarette smoking 
 
  stopping is associated with reduced risk  of heart disease. 
 
 The incidence  is about 36%. This is not changed by age. 
 This is not also affected by race , age and gender and  
ethenicity.  Cigarette smoking cessation is associated  
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with more beneficial effect when compared to taking  
 
aspirin. This is also superior to beta blockers, statins and  
 
ace inhibitors. Smoking cessation have much benefits  
 
when they are combined with  healthy exercise. They also 
 
 have increased benefits when smoking  abstinence is  
 
combined with healthy foods. Good results were obtained 
 
 when nicotine chewing gums are used instead of  
 
cigarettes. But low smoke cigarettes does not decreases  
 
the risk of smoking related problems. stopping  the habit  
 
of smoking is associated with reduced incidence of cardio 
 
 vascular problems. This is confirmed by many trials. But  
 
the risk of development of various cancers is unchanged. 
 
 There is increased risk for developing cancer of the  
 
pancreas. Similarly there is increased risk of developing 
 
  chronic obstructive pulmonary disease even after 
 
 stopping the habit of smoking. 
 
 
Nicotine: 
 
The main component of smoke is nicotine. It is an  
 
                    alkaloid. It is mainly present in the family of solanaceae 
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. 
                    It has action that resembles cholinergic activities. It acts  
 
on the nicotinic receptors of the cholinergic nervous  
 
system
[30]
. At very low doses it stimulates the central  
 
nervous system. But in high doses it affects the central  
 
nervous system. This causes many unwanted side effects. 
 
 This substance is responsible for the addiction of persons  
 
to the cigarettes. This name is derived from the name of  
 
the  tobacco plant. Tobacco plant is called as Nicotiana.  
 
Adolf pinner described its molecular formula
[31]
. Nicotine  
 
is a substance that is soluble in water. It is not soluble in  
 
water. It is miscible in water. The salts of nicotine is  
 
soluble in water. The levo rotatory form of this compound  
 
is more active than the other form.  
 
Synthesis of nicotine: 
 
Nicotine is synthesized from 2 main compounds. They are  
1. Niacin 
2. Pyrollidium ion. 
Synthesis of niacin is from NAD pathway. Synthesis of 
pyrollidium ion is from tropane pathway
[32]
. 
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Nicotine once it smoked reaches the alveoli. From there it 
is rapidly absorbed from capillary system. Then it 
reaches the brain by crossing the blood brain barrier. The 
half life of nicotine is found to be around 2 hours
[33]
. 
Nicotine that enters the human body is dependent on the 
following  
1. Type of smoked substance like cigars , beedis. 
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2. Presence or absence of filters. 
Nicotine acts on the cholingeric receptors present in the 
central nervous system. They are also present in adrenal 
medulla. They are also present in autonomic ganglia. It is 
mainly metabolized by the enzymes present in the liver. 
They are called as cytochromes.The active product of 
nicotine is cotinine.  The main end products are  
1. Cotinine  
2. Nor nicotine 
3. Nicotine glucuronide. 
They are mainly excreted through urine. 
Mechanism of action: 
Central nervous system : 
Nicotine acts on the receptors of the central nervous 
system. They are anticholinergic by action. It also 
activates the release of other neuro transmitters like 
dopamine. This mechanism is responsible for the 
euphoria caused by nicotine.  
Cigarette smoking and atherosclerosis. The release of 
dopamine is through cholinergic pathways. The 
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activation of cholingergic receptors in the central nervous 
system is more than the skeletal system. Nicotine also 
contains inhibitors of the  enzyme mono amino 
oxidase
[34]
. Dopamine , serotonin and epinephrine are 
mainly metabolized by this enzyme. This  leads to 
increase in half life of dopamine. This leads to prolonged 
euphoric effect of nicotine. 
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Sympathetic nervous system: 
 
Nicotine also has its action on sympathetic nervous 
system. It causes the release of  
Acetyl choline from preganglionic fibres. This acts on the 
adrenal medulla which is the largest ganglia. Epinephrine 
is released from adrenal medulla into blood. This acts on 
various organ systems leading to increased heart rate , 
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increased blood pressure and higher blood glucose. 
Acetyl choline released by nicotine causes the entry of 
calcium inside the chromaffin cells. This leads to the 
release of epinephrine from the cells of adrenal medulla. 
This process is called as exocytosis
[35]
. 
Toxicology: 
The lethal dose of nicotine in humans is found to be 50 
mg
[36]
. The range varies from 30 to 60 mgs.caffiene is 
also an alkaloid. But compared to caffeine, nicotine is 
very toxic as the lethal dose is very small. Nicotine 
promotes the formation of cancers in various aspects. It  
1. Increases the production of growth factors. 
2. Inhibits the apoptosis of the cells by continuous 
stimulation of cell cycle by sympathetic pathway. 
3. It also promotes the vascularisation of tumour 
cells. 
In pregnant woman nicotine adversely affects the fetus. It 
causes the vasospasm of umbilical arteries. This leads to 
poor perfusion of fetus. As a result the growth of brain of 
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fetus is affected. Brain metabolism is also affected. These 
manifests as poor  neuro behavior of the newborn.  
Nicotine exerts its action in the brain through dopamine. 
When the smoking habit is suddenly stopped the levels of 
dopamine in the brain decreases. As  a result the 
dopamine receptors and oversynthesised to counteract the 
deficiency of dopamine. This leads to increased 
sensitivity of dopamine receptors to dopamine in the 
brain. 
Detection of use: 
Serum levels of the nicotine levels are important in a 
medico legal investigation. But serum levels of the 
nicotine increases in persons who are exposed to passive 
smoke. 
Health effects of nicotine: 
The health effects achieved through smoking are called as 
smokers paradox
[37]
. The mechanism of action for such 
paradox are poorly understood.  After detailed researches 
they found out that it is due to the substance nicotine. 
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Nicotine whether consumed by a person either in the 
form of smoke or patches have the same effect. 
Smoking offers a beneficial role in a variety of diseases. 
These include 
1. Ulcerative colitis 
2. Allergic asthma 
3. Pre eclampsia[38] 
4. Atopic disorders 
5. Kaposi sarcoma 
Nicotine present in the smoke is a vasoconstrictive 
substance. In inflammation there is release of cytokines 
leading to vasodilatation. But due to nicotine the 
vasodilatory effects of the inflammation are prevented. 
Thus nicotine is very useful in many inflammatory 
diseases and diseases where vasodilatation is the main 
pathogenic factor.smoking is also very useful in the 
treatment of  major depressive disorders. Smoking 
increases the risk of alzheimers disease where as the 
nicotine present in the smoke reduces the formation of 
alzheimers disease
[39]
. Smoking is also tried in the 
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treatment  of obsessive and compulsive disorder and the 
results are successful in small scales. Smoking decreases 
the risk of ulcerative colitis but the risk of developing 
crohn’s disease is increased.  
Psycho active effects: 
Nicotine has two main psycho active effects. They are 
1. Stimulant effect 
2. Relaxant effect[40] 
These effects are mainly due to the release of neuro 
transmitters in the brain. They are also due to the release 
of glucose from liver and also release of adrenaline from 
the adrenal cortex. Smoking is also associated with 
reduced appetite. This leads to loss of weight in smokers. 
The time taken for nicotine to reach the brain from lungs 
to brain is just seven seconds. Once it reaches the brain it 
causes the release of various neurotransmitters. They 
include mainly epinephrine , acetyl choline and  
norepinephrine. The other important ones are dopamine 
and serotonin. Endorphins also play a role in the 
stimulant effect. 
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Alertness and arousal are caused by norepinephrine. 
Concenteration is increased by nicotine. Memory is 
thought to be increased by acetyl choline. Relaxation is 
mainly mediated by serotonin.  When the smokers inhale 
short puffs the effect achieved is stimulation. This is due 
to the release of dopamine in the nerve terminals of the 
central nervous system. When the subjects take deep puff 
the effect achieved is relaxation. This is mainly due to the 
release of the serotonin released in the nerve terminals of 
the central nervous system.  
Nicotine – an insecticide: 
During the period of world war II nicotine is mainly used 
as an insecticide. After the world war was over the usage 
of nicotine as an insectide has been drastically reduced. 
This is mainly due to the synthesis of the insecticides that 
have reduced toxic effects to the humans and animals. 
 
 
History of smoking: 
 
The habit of smoking was first discovered by the people  
 
of America . they were called as native Americans.they  
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smoked during ceremony. They also thought that  
 
smoking had medicinal purposes. Coloumbus then  
 
brought the leaves of tobacco to Europe. Europeans had  
 
their habit of smoking from the middle of sixteenth  
 
century. Nicotine was discovered by jean nicot. The drug 
 
 was given its name after the scientist. Smoking began a  
 
common recreational practice in france then in Portugal. 
 
 The cultivation of tobacco first began in the united states  
 
of America as a cash crop. This was done by john rolfe in  
 
1612. Within few years it  became the main export  
 
business of America. Initially tobacco was used in the  
 
form of cigars. They are also chewed. Cigars were not  
 
popular during the initial period. Cigarettes were very  
 
popular since 19
th
 century. Cigarette smoking was initially  
 
considered to be a positive habit. Even many physicians  
 
prescribed smoking as a good medicine. The negative  
 
aspects of smoking came to light only after 20
th
  
 
century.during the year 1930 it was found that smokers  
 
can’t live as long as non smokers. Many researches were  
 
done on this. Cancer society of Aerica has found that  
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smoking can lead to many cancers. But there is evidence  
 
to prove this. The causal relationship between smoking   
 
and cancer could not be established . The uneducated  
 
people could not understand the statistical researches.  
 
Tobacco research council was established and it published  
 
the adverse effect of smoking. Low tar cigarettes were  
 
introduced then and the sales increased then. The causal  
 
relationship between smoking and cancer was established  
 
in 1964. It was concluded that smokers are at a high risk  
 
of developing lung cancer than the nonsmokers. Similar  
 
results were esbablished in females too. Some of  the  
 
substances were specifically  found to be carcinogens in  
 
smoking . these include arsenic and cadmium.  General  
 
warning on the labels of cigarette packs were introduced  
 
since 1964. Advertisement of cigarettes were stopped  
 
since 1971. The habit of smoking in flights were stopped  
 
since 1990. Orders were given to FDA to regulate the  
 
sales of cigarettes to minors. 
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Smoking in india: 
Smoking in india was described since 2000 BC. Cannabis 
smoking was practiced since before Christ . initially 
smoking was done in the form of fumigation. Smoking 
was also practiced in the form of Homa. In this method 
various substances were put into fire including milk , fish 
and skin of snakes. Initially smoking was practiced as a 
form of medicine in ayurvedha . tobacco smoking in 
india was introduce in 17
th
 century. Since then it merged 
with old practice of smoking. Smoking in public places 
was prohibited since November 2001. Smoking 
ipracticed by 12 crore people in india. This contributes to 
12%  of the total smokers in the world. About  thirty 
percent of the Indian males smoke. More than nine lakh 
smokers in india die every year. Females also smoke in 
india. But the proportion is  very less. It is about 2 to 4%.  
Cigarette smoking is highly practiced in the state of 
jammu and Kashmir. Beedi smoking is more in the state 
of uttarkhand. Statuatory warning in the packs of 
cigarettes were introduced in the year of 1975 by the 
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supreme court of india. Smoking within 100 yards from 
educational places were introduced since December 1  
2004. In india Chandigarh is called as the smoke free 
city. Similarly shimla is trying to be the second smoke 
free city. Smoking in public places has been banned from 
October 2008. This includes places like cinema theatres , 
pubs, bars ,temples , public transport places like bus 
stand , railway station , airports and harbours. Pictorial 
warning on the cigarette pack was introduced in may 13 
2009. This involves a demonstration of a picture showing 
the adverse effects of smoking. Video advertisement 
showing the harmful effects of smoking were introduced 
since October 2
nd
 2012. These were shown before the 
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start of the movie and during intervals. 
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MAJOR ADVERSE EFFECTS OF SMOKING:  
 
Smoking is responsible for many adverse effects out of  
 
which the following four are more important. 
 
1. Cancer 
 
2. Non cancerous lung diseases 
 
3. Atherosclerotic diseases of aorta and coronary 
blood vessels. 
 
4. Toxicity to reproductive system 
 
 
The most important ingredient of smoking is nicotine. It is 
a psychoactive drug 
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which is responsible for craving during the time when a 
person makes an attempt 
 
to stop smoking. 
 
Cancer: 
 
Smoking is responsible for the following cancers. 
 
1. Lung 
 
2. Oesophagus 
 
3. Oral cavity 
 
4. Larynx 
 
5. Bladder 
 
6. Pancreas. 
 
 
The most common cancer associated with smoking is lung 
cancer. 
 
The risk of developing cancer depends on 
 
 the number of cigarettes smoked daily 
 
 the duration of smoking 
 
 active or passive smoking 
 
 age at the onset of smoking 
 
 factors associated with smoking  like 
 
 
1. Alcohol 
 
 
 
 
55 
 
2. Radiation exposure 
 
3. Asbestos 
 
4. Certain Viral infections. 
 
 
The main carcinogenic effects of smoking is attributed to 
 
1. Mutation 
 
2. DNA damage. 
 
These two process leads to malignant transformation of 
mammalian cells into 
 
malignant cells. 
 
When condensed cigarette concentrates are applied to the 
shaved skin of mice 
 
most of the mice developed  skin cancers. 
 
Each puff contains about 30 to 70 ml of smoke. The main 
chemical ingredients are 
 
1. Benzo(a)pyrene  (bap)  such as dibenzo-acridine\ 
 
2. N-nitrosamines such as NDMA 
 
3. Aromatic amines such as 4-aminobiphenyl 
 
4. Aldehydes such as formaldehyde 
 
5. Organics such as benzene 
 
6. Inorganic compounds such as arsenic, nickel, and 
chromium. 
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These substances can induce tumours by either acting as 
an 
 
1. Initiators :  initiating tumour development 
 
2. Promoters:  cant initiate but promote the 
development of previously initiated 
 
cancers. 
 
Certain substances in smoke are known to produce 
specific tumours. 
 
They are 
 
I. TNSA: 
 
It produces cancers of 
 
a. Lung 
 
b. Larynx 
 
c. Oesophagus 
 
d. Pancreas 
 
 
II. Aryl amines: 
 
It produces cancer of bladder. 
 
III. Benzene: 
 
It produces leukemia. 
 
NON CANCEROUS LUNG DISEASES: 
 
The main non cancerous lung disease produced by  
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smoking is chronic obstructive lung disease. This occurs  
 
after repeated injury to lung tissue by smoke. During  the 
 
early years of smoking there is no symptoms experienced  
 
by smokers but pulmonary function tests revealed 
 
 abnormalities. There is a dose dependent change in  
 
pulmonary function tests and the duration of smoking  
 
concluded by many studies. Over a period of 2 decades or 
 
 more chronic obstructive lung changes begins to appear. 
 
This includes 
 
1. Mucous hypersecretion leading to cough with 
expectoration 
 
2. Airway thickening and inflammation of small 
airways 
 
3. Emphysema : abnormal dilatation of terminal 
airways with 
 
thinning of  airways causing obstruction of airways during 
 
expiration. 
 
As a result of these changes life style of smokers begins to  
 
change leading to morbidity.Each person develops any  
 
type of changes described in the above spectrum.  
 
Some persons will have more cough with expectoration  
 
while some others develop airway obstruction features. At  
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the endstage all persons  will have features of all the  
 
 3stages of spectrum..The mechanisms by which smoking  
 
produces changes in respiratory tracts includes 
 
1. Toxicity to cilia: 
 
Cilia along with the mucous secreted by respiratory  
 
epithelium is responsible for propelling the foreign body  
 
that enters the respiratory tract. By damaging cilia  
 
smoking causes stagnation of mucous in respiratory tract .  
 
this leads to the growth of pathogenic organism in the  
 
mucous plug leading to the damage of the walls of the  
 
respiratory tract leading to abnormal and irreversible  
 
dilation  of the  small sized bronchioles. 
 
2. Inflammation: 
 
Smoking also causes damage to respiratory tract by  
 
inflammation of the airways. The main mechanism by  
 
which smoking promotes inflammation is by means of the  
 
oxidative substances present in it. Smoke contains an  
 
enzyme called as elastase which breaksdown the elastic  
 
material present in the walls of lumen. Smoke also  
 
inhibits alpha 1 antitrypsin a substance which inhibits the  
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enzyme elastase thus promoting the destruction of  
 
airways. Smoke contains many other volatile and non  
 
volatile substances which damages the respiratory tract  
 
.these include 
 
 Hydrocarbons 
 
 Aldehydes 
 
 Ketones 
 
 organic acids 
 
 Phenols 
 
 Cyanides 
 
 Acrolein 
 
 nitrogen oxides. 
 
Some agents are concerned with the production of  
 
excessive mucous production while some others are  
 
concerned with small airway abnormalities while the rest  
 
are associated with emphysematous changes. 
 
Atherosclerotic heart disease: 
 
Smoking is associated with the formation of  
 
atherosclerotic plaque formation and its subsequent  
 
rupture and formation of thrombosis. This occurs in any  
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of the main vessels like coronary circulation , cerebral  
 
vascular tree , aorta and in limb vessels.The main site 
 of  atherogenesis is coronary circulation which may  
 
present in the form of stable or unstable angina , heart  
 
failure , sudden death. If it occurs in cerebral circulation  
 
this is called as stroke . when this occurs in limb vessels  
 
as peripheral vascular disease. The process by which  
 
smoking promotes atherogenesis are 
 
1. Reducing the value of HDL cholesterol. 
 
2. Increasing the value of LDL cholesterol. 
 
3. Increasing the oxidation of  LDL cholesterol. 
 
4. Promoting the entry of LDL cholesterol in 
endothelium. 
 
5. Increasing the adherence of  platlets to 
endothelium. 
 
6. Increasing the formation of  blood clot thereby 
occluding the 
 
already narrowed vessel. 
 
The substances which promotes the formation of 
atherogenesis are 
 
1. Nicotine: 
 
Nicotine increases the heart rate and circulation. It  also  
 
causes injury to the endothelial lining . 
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2. Carbon monoxide: 
 
It binds with hemoglobin and reduces the oxygen carrying 
 
capacity of cells and keeps the myocardium in the state of  
 
hypoxia. 
 
3. Polycyclic aromatic hydrocarbons: 
 
4. Free oxygen radicles: 
 
It damages the endothelium and promotes the formation 
of atherosclerosis. 
 
Cigarette smoking and reproduction: 
 
Smoking affects reproduction in both sexes. In males it  
 
causes impotence. The cause of impotence may be due to  
 
the vascular disease affecting the vessels supplying the  
 
genitalia. In females it causes infertility. This may be due  
 
to reduced motility of the eggs in fallopian tubes or it may  
 
be due to recurrent infections of the fallopian tubes due to  
 
suppression of immunity by smoking. 
 
Cigarette smoking affects the maternal and fetal outcome.  
 
It causes 
 
1. Spontaneous abortion 
 
2. Low birth weight 
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3. Preterm delivery 
 
4. Bleeding during pregnancy. 
 
Nicotine is the main substance causing all these problems. 
 
  Poor weight gain During pregnancy due to smoking is  
 
also the mechanism for low birth weight. Smoking also  
 
causes vasospasm of the umbilical arteries . carbon  
 
monoxide present in the smoke can cross the placenta and  
 
binds with fetal hemoglobin and causes poor oxygen  
 
delivery. Smoke contains cyanide which also causes 
 
 harmful effects. Smoking women experience early 
 
 menopause compared to non smokers while heavy  
 
smoking women have early menopause compared to light  
 
smoking women.. 
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Smoking also associated with development of rheumatoid  
 
arthritis.Smokers have a very high risk of developing  
 
diabetes mellitus compared to non smokersSmokers have  
 
reduced bone mineral density leading to the development  
 
of osteoporosis and also early tooth lossSmoking is also  
 
associated with the early onset of cataracts and also age  
 
related macular degeneration. 
 
 
Comparison of type of smoking: 
 
Smoking may be in the form of  cigars , beedis and  
 
cigarettes.  Nothing is safer than other in causing adverse 
 
 effects. Similarly menthol coated cigarettes have no 
 
 advantage over other cigarettes in fact they are more  
 
worse than  normal cigarettes.Since they have cooling  
 
effect they suppress cough reflex and make the person to  
 
take more and more puffs. Smoking even as low as 1  
 
cigarette per day is associated with definite  
 
cardio vascular risks. Similarly e – cigarettes are also 
 
 not safer than normal cigarettes . their ingredient is not  
 
known. They also contain nicotine which leads to  
 
addiction. 
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Smoked tobacco in India 
 
Beedis: 
Beedis are substances which is made of dried tobacco  
wrapped inside an rolled to form a beedi
[41]
. Beedis are  
smaller in size when compared to the cigarettes as a result  
of which people smoke more beedi to attain the  
satisfaction produced by nicotine. Beedi rolling serves as  
a major source of income in running familes in many  
villages of India.The effects of both smoking  
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cigarettes and inhalation of tobacco flakes is  
similar.Hence there is an increase in the risk of cancers  
specifically lung cancer to the members of the family. 
Cigars and Cigarettes: 
Cigars-These are nothing but a wrap of tobacco leaf 
inside which dried tobacco  
is filled. 
Cigarette-Here the roll of tobacco instead of the leaf is  
wrapped in a Paper
[42]
.Cigarettes in the market come with  
a lot of variety for example: with filters,low tar,menthol  
and even flavoured ones which makes the customers fall  
for and producing a misconception that cigarette smoking  
thus causes less harm to our health.People belive that  
cigars are smaller in size and causes less harm but are  
unaware that  a large cigar can contain so much tobacco  
so it becomes equal to one whole packet of cigarette.  
Smoking cigarette is on an alarming rise and is becoming  
common even among teenage girls and young women. 
Chilum: 
In this type tobacco is smoked in a clay pipe.This type  
poses the person to an increased risk of oral cancer and  
lung cancer.A group of people share a chillum and hence 
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 apart from increasing the risk of oral cancer it also makes  
them vulnerable for cold and other respiratory illnesses. 
Hookah: 
This is also an unsafe way of smoking and the mechanism  
is the tobacco is heated by a device and before the smoke  
is inhaled it passes through water.Though this type of  
smoking was declining for a period it is now again on the  
rise.It is available in flavors like apple, chocolate.etc in 
 coffe shops as they depict a sign of royalty and  
prestige.This pattern of smoking which inclines the   
person more towards addiction is used more  
commonlamong the college boys and girls. 
Chutta smoking and reverse chutta smoking: 
These are smoked in the coastal areas of India and are  
nothing but coarse tobacco cigars. 
Reverse Chutta smoking: 
In this method the burning end of chutta is kept in the  
mouth and the smoke is inhaled.This has the highest risk  
of oral cancer 
 
 
 
 
 
 
 
67 
 
REVIEW OF LITERATURE 
 
1.RELATIONSHIP OF CIGARETTE SMOKING 
AND SNUFF DIPPING TO PLASMA 
FIBRINOGEN,FIBRINOLYTIC VARIABLES AND 
SERUM INSULIN – THE NORTHERN SWEDEN 
MONICA STUDY 
            This study consisted a randomly selected  
population consisting of 604 males and 662 females  
between the age 25 and 64 years.They were grouped as  
regular smokers(>1cigarette /day),ex-smokers,snuff  
dippers and non -tobacco users.Men who smoked had  
0.34g/l(95% CI 0.17to 0.49) higher fibrinogen level than  
non tobacco users.The  number of cigarettes smoked  
correlated with plasma fibrinogen levels.Female smokers  
had significantly higher fibrinogen levels than ex-smokers  
.The Difference when compared with non smokers was  
not that significant. 
Conclusion: cigarette smoking is associated with   
 Higher fibrinogen levels 
 
 Normal glucose tolerance and insulin levels 
 
 Unaltered fibrinolysis 
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 Use of smokeless tobacco as moist oral snuff,does 
not appear to affect these potential cardiovascular risk 
factors. 
 
2.ANNALS OF EPIDEMIOLOGY,MAY 
2001,ORIGINAL REPORT – SMOKING,OTHER 
RISK FACTORS AND FIBRINOGEN LEVELS 
EVIDENCE OF EFFECT MODIFICATION 
Purpose- This study aims at denoting that smoking  
modifies the association between the traditional risk  
factors of early atherosclerosis such as dyslipidemia, 
hypertension,or diabetes mellitus,with fibrinogen a risk  
factor more closely associated to plaque progression and  
thrombosis. 
 
Methods- the sample for this study was collected from  
the MONICA Augsburgpopulation survey of 1989/90  
which included 1840 men and 1784 women aged between  
25 to 65 years. Plasma fibrinogen concentration was  
determined by nephelometry. 
 
Results- 
 Fibrinogen levels were higher in women than in 
men and higher insmokers than in non smokers. 
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 The effect of smoking was greater in men.The 
elevation of meanadjusted fibrinogen levels in men was 
significantly higher in smokers than in non smokers. 
 
 
 By contrast smoking in women showed 
significantly stronger impacts only with regard to the 
association of dyslipidemia and fibrinogen. 
 
Conclusion 
Smoking contributes more than additively to the strong  
influences od risk factors on fibrinogen levels.These data  
confirm that smoking is a dominant determinant of  
fibrinogen levels. 
 
3.EFFECTS OF SMOKING AND ABSTENTION 
FROM SMOKING ON FIBRINOGEN SYNTHESIS 
IN HUMANS: 
The significant risk factors for development of  
cardiovascular disease are both smoking and  
hyperfibrinogenemia.Two studies described aims to  
establish the mechanism responsible for  raised plasma  
fibrinogen concentration seen in smokers. 
The absolute rate of fibrinogen synthesis(ASR) was  
increased in smokers than non smokers and the  
plasmalevel of fibrinogen correlates significantly with  
fibrinogen synthesis.On the contrary  plasma albumin  
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concentrations were low in smokers than non smokers  
with no difference in the rates of albumin synthesis  
between the two groups.There was marked fall in plasma  
fibrinogen concentration and a significant reduction in  
ASR in previously chronic smokers who stopped smoking 
 for 2 weeks. 
                Large scale studies have consistently  
demonstrated that an increased plasma fibrinogen  
concentration is an independent risk factor for a  
cardiovascular event for which the Northwick park heart  
study is a goodexample.Cigarette smokers is a group of  
population which consistently exibhits increased  
incidence of vascular problems.Cigarette smoking is a  
independent risk factor for stroke and ischaemic vascular  
disease and also doubles the fatalities from coronary heart  
disease.The most common aberration of the hemostatic  
system found in smokers is raised plasma fibrinogen  
concentration and the clinical significance has been  
highlighted by several inveatigators.Kannel et al for  
example used data from the Framingham study to estimate  
that 50% of smoking associated with ischaemic heart  
disease may be mediated through the deleterious effects of  
fibrinogen.Though attention has been focussed on the  
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relationship between smoking and increased plasma  
fibrinogen level the mechanism has not been elucidated. 
           This paper described two studies which used  
isotope methodology to Perform in-vivo investigations to  
know about the influence of cigarette smoking on  
fibrinogen synthesis. 
            In the first study the rates of fibrinogen synthesis 
was compared in groups of smokers and non-smokers. 
Whereas in the second study a group of chronic smokers  
who were abstained from smoking for 14days were  
chosen to determine if short term cessation affected  
fibrinogen synthesis.Through this study it was also  
possible to investigate the synthesis of albumin in  
smokers.           
 
Methods 
 All the participants were healthy and medication  
free.exclusion criteria included diabetes,overt liver,kidney  
or thyroid dysfunction,infection,routine consumption of  
aspirin,lipid lowering or fibrinolytic drugs,a history of  
vascular disorders,obesity,hypertension and  
hyperlipidemia. Since an acute phase response alters  
fibrinogen metabolism participants with plasma  
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concentrations of C-reactive protein >10mg/l were  
excluded.All measurements were performed after patients  
fasted for 12 hrs.Since variables like age, sex and body  
mass index were thought to influence plasma fibrinogen  
concentration for study 1 these particulars was matched  
between eight male smokers and non smokers. To  
standardize smokers were asked to retain smoking 1hr  
before the measurements were made. 
               For study 2 eleven male chronic smokers within  
the specific criteria were recruited. Measurements were  
performed before and immediately after a 2 week period  
of complete abstention from smoking.Participants were  
asked  to refrain from smoking for 9 hrs.Urinary  
concentration of cotinine which is ametaboliote of  
nicotine was measured on two occasions during smoking  
abstinence to monitor the compliance to non smoking. 
 Urinary cotinine levelswere compared with  a reference  
range obtained from a group of non-smokers. Participants  
whose urinary continence level exceeded the maximum 
 value of this range(55µg/ml) were excluded from the  
study. 
 
Measurement of the rate of fibrinogen synthesis 
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The rate of fibrinogen synthesis was measured according  
to the methods of balmer et al following injection of a  
specific type of phenyl alanine.The blood samples were  
then taken at specific times to know the isotopic  
enrichment of the plasma free amino acid and newly  
synthesised protein. 
                 The rates of fibrinogen synthesis was expressed  
as both as fractional and absolute rates.(FSR and ASR).  
Plasma fibrinogen and serum C-reactive protein  
concentraions were measured immunologically by 
 automated –laser rate nephelometry. 
Results 
Study 1- 
 The plasma fibrinogen concentration was on an  
 
average 10%higher in smokers than the non-smokers  
 
but did not show muchstatistical significance. 
 
 The rate of fibrinogen synthesis expressed as  
 
percentage of plasma fibrinogen  pool was higher in  
 
smokers than non-smokers which was also not  
 
statistically significant. 
 
 The absolute rate of fibrinogen synthesis, i.e. the  
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amount of fibrinogen synthesised by the liver per day  
 
was significantly greater in smokers when compared  
 
with the non-smokers. Smokers also had significantly  
 
lower plasma albumin concentrations when compared  
 
with the non-smokers. 
 
Study 2- 
      Eight of the eleven male participants hasd successfully  
completed the study.The others were excluded due to 
 development respiratory infection and elevated urinary 
 cotinine levels.The mean urinary cotinine levels of the  
successful abstainers was 0.20±0.03µg/ml,which  
suggested they had compiled with the non-smoking  
regimen.The increase in weight seen in smokers who had  
abstained from somking was significant to the present 
 study because it resulted in increased estimated plasma  
volumes for use in the calculation of  
fibrinogen ASR.  
 A fall in plasma fibrinogen concentration was  
 
observed in all the participants(smokers) as they had  
 
abstained from smoking as per the protocol, an average  
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reduction of 19%. 
 
 The average decrease of FSR was 14% due to  
 
cessation from smoking. 
 
 The average reduction in fibrinogen ASR was 33%  
 
following smoking cessation. 
 
 Discussion 
The major risk factor for developing  
cardiovasculardisorders is hyperfibrinogenemia  
bypromoting a multitude of atherogenic and thrombogenic  
processes,which is thought to be as important as raised  
plasma cholesterol.The mechanisms by which fibrinogen  
and its derivatives are thought to accelerate athero  
thrombogenesis include : 
 Stimulation af vasoactivity 
 
 Alteration of prostaglandin metabolism and tissue 
oxygenation  
 
 Promotion of platelet hyperactivity and erythrocyte 
aggeregability 
 
 Initiation and sustained growth of atherosclerotic 
lesions. 
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                   As a consequence ,researchers recommend  
that plasma fibrinogen should be included during the  
assessment of cardiovascular risk. The stongest known  
environmental influence on plasma fibrinogen  
concentration is smoking and has consistently been 
 linked to the development of elevated  
plasma fibrinogen.Conversely,cessation from smoking  
results in a rapid reduction in plasma fibrinogen which  
subsequently may reamin elevated for several years.This  
paper aimed to establish if the hyperfibrinogenemia in  
smokers is accompanied by an increased rate of synthesis  
and, conversely, whether synthesis is reduced by short-  
term smoking cessation. Thus the result i.e. higher  
plasma fibrinogen concentrations ofsmokers compared  
with non-smokers and the significant fall in plasma 
fibrinogen concentration with two weeks abstention  
from smoking are inaccordance with the previous  
study.The elevated levels of plasma fibrinogen 
concentration in smokers  also correlated with elevated  
levels of fibrinogen synthesis.The rates of fibrinogen  
synthesis  were reduced to levels comparable with those  
of non-smokers after abstention .These results from 
both studies support the proposal that smoking induces  
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fibrinogen synthesis and this effect can be reduced by  
abstention from smoking.The rate of synthesis of  
fibrinogen and the rate of removal of fibrinogen from the  
plasma determines the fibrinogen concentration in the  
plasma.It is clear from the studies that the rate of  
synthesis of fibrinogen is increased in smokers but the  
rate of removal could not be measured.The magnitude of  
changes in the ASR were greater than the observed  
differences in plasma fibrinogen concentration between  
smokers and non-smokers or absatiners ,suggesting that  
the rate of disappearance of fibrinogen from the plasma  
was also elevated in smokers when compared with non- 
smokers or abstainers.The difference in the fibrinogen  
ASR of smokers and non-smokers(study1) andthe  
reduction in fibrinogen synthesis which occurs from  
abstention from smoking(study2) are due to several  
biochemical mediators.Chronic smokers exibhit a  
mild,but sustained acute phase response,characterised by  
increased plasma concentrations of positive acute phase  
proteins such as fibrinogen and alpha-1- 
antitrypsin.Tobacco smoke inhalation causes a persisting  
inflammatory insult to the cells which is the reason for  
this response.The increase in plasma concentration of  
 
 
 
78 
 
fibrinogen during the response  is attributed to increased  
fibrinogen synthesis via a stimulation of transcriptional  
activity.Cytokines are thought to be the important  
mediators of this response of which specifically  
interleukin-6 may be the reason behind the enhanced rate  
of fibrinogen production in smokers.In smokers the  
plasma concentration of interleukin-6 has found to be  
 
elevated. Cathecholamines may also be mediators of the  
smoking effect on fibrinogen synthesis in addition to 
 cytokines.Cathecholamine release is stimulated by  
smoking and studies have demonstrated that epinephrine  
increases fibrinogen synthesis directly possibly by  
enhancing m-RNA synthesis. Since incubation of human  
liver slices with fatty acids accelerates incorporation of  
amino acids into fibrinogen and plasma non-esterified  
fatty acid concentrations are elevated after smoking it is  
suggested that fatty acids may also have a role in  
enhancing the fibrinogen production in smokers. The  
above said mechanism is facilitated by thrombin. This is  
proved as the injection of thrombin into mice has resulted  
in non-esterified fatty acid concentrations and a  
stimulation of fibrinogen production and thrombin  
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generation is induced by smoking. 
Conclusion- 
 The increase in the rate of fibrinogen synthesis  
 
seen in chronicsmokers is atleast partially responsible for  
 
the hyperfibrinogenemia. 
 
 Short term cessation from smoking results in  
 
significant reduction in the rate of fibrinogen synthesis. 
 
4.SMOKING CESSATION AND 
CARDIOVASCULAR DISEASE RISK 
FACTORS:RESULTS FROM THIRD NATIONAL 
HEALTH AND NUTRITION EXAMINATION 
SURVEY 
Background 
Smoking is considered to be the important risk factor not  
only for development but also for the progression of  
cardiovascular events.The high levels of inflammatory  
markers and atherosclerosis is attributed to smoking. The  
impact of smoking cessation on levels of inflammatory  
markers have been widely examined by various  
studies.The degree and rate at which inflammation  
decreases after smoking cessation is not clear. 
                      A total of 15489 individuals participated in  
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the Third National health and Nutrition Examination  
Survey(NHANES III).From this study the association  
between smoking and and smoking cessation on levels of  
inflammatory markers and traditional cardiovascular risk  
factors was analysed.Of the inflammatory markers in  
particular changes in C-reactive protein, fibrinogen,  
albumin, white blood cell count were examined. A  
temporal and dose dependent relationship was  
demonstrated between the inflammatory markers to  
smoking and smoking cessation. The inflammatory and  
traditional risk factors improved with decreased intensity  
of smoking. Moreover inflammatory markers resolved  
more slowly than traditional cardiovascular risk factors  
with increase in time since smoking 
 cessation. 
Introduction- Through several  pathways in both a  
duration and dose dependent manner smoking accelerates  
atherogenic cardiovascular disease. 
Smoking incites: 
 Endothelial cell dysfunction 
 
 Foam cell proliferation in tunica media 
 
 Enhances platelet aggregation  
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 An immunologic response to vascular injury 
 
 Depresses high-density lipo-
protein(HDL)cholesterol 
 
 Oxidative stress leading to lipid peroxidation 
 
 Impairs lipoprotein metabolism 
 
                   There is a significant increase in C-reactive 
 protein, white blood cell count, fibrinogen whereas  
decrease in serum albumin during the acute phase of  
inflammatory states. With regard to the future  
cardiovascular events the acute inflammatory markers  
have found to be both predictive and prognostic. The most  
important inflammatory marker in the process of  
atherosclerosis is C-reactive protein. It has been found  
that CRP is also produced at the site of atherosclerosis by  
smooth muscle cells. C-reactive protein in the vessel wall  
induces expression of adhesion molecules on endothelial  
cells. Thus increases monocyte chemotactic protein-1  
which inturn attracts the monocytes and T cells into the  
vessel wall.C-reactive protein is also a mediator in the  
pathogenesis of atherosclerotic cardiovascular disease. 
                   From the Third national Health and Nutrition  
Examination  Survey(NHANES III)the association  
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between smoking and smoking cessation and the levels of  
inflammatory markers and traditional risk factors was  
tested.The association between decreased  smoking and  
increased time since smoking cessation to changes in the  
inflammatory markers – C-reactive protein, fibrinogen,  
albumin, white blood cell count and the traditional risk  
factors-total cholesterol, triglycerides, HDL cholesterol,  
systolic blood pressure. 
 
The primary aims are: 
 To denote the excess cardiovascular risk associated  
 
with smoking and any associated decline in risk with  
 
smoking cessation by investigating changes in C-reactive  
 
protein. 
 
 Whether the inflammatory markers observed  
cardiac risk reduction following smoking cessation from  
smoking. 
Methods- 
Study population-NHANES III was a study conducted  
between 1988 and 1994.The NHANES III population  
included 19,618 persons some were excluded due to  
various reasons and data for 15,489 persons were  
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analysed. Several clinical factors were analysed based on 
 self reporting by the participants, questionnaires and  
clinical examination. Investigations were taken  
for dieases like diabetes mellitus, hypertension with  
specific cut-off values. Serum cholesterol and triglyceride  
values were measured enzymatically. More importantly,  
based on both self-reporting and serum cotinine levels  
the study population was classified.Persons with serum  
cotinine levels more than 56.8nmol/land those who gave a  
history of current smoking were consideredcurrent  
smokers.This group was in turn divided into four roughly  
equal groups based on number of cigarettes smoked per  
day: 1-9,10-19,20-29 and more than 30 cigarettes per  
day.Former smokers were classified by years  
sincesmoking cessation: <1, 1-3, 3-5, 5-7, 7-9 and  >9  
years since smoking cessation.Those with serum cotinine  
levels less than 56.8nmol/l were denoted as never  
smokers.Smokers at the lowest dose intensity level were  
those Passive smokers with cotinine levels over  
56.8nmol/l. 
                       Nephelometer was used for measuring C- 
reactive protein.Fibrinogen was measured using a  
quantitative assay of clotting time. Mantel tests for trend  
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was used for knowing the relationship between  
both time since smoking cessation and smoking intensity  
and the assessment of each of the outcomes. 
Three sets of tests were performed: 
 by cigarettes per day among current smokers 
 
  by time since cessation among former smokers 
 
 despite the potential nonlinearity between the 
groups among smokers, former smokers and non-
smokers . 
 
Results 
Total sample consisted of 15489 persons  of which 3459  
were classified as former smokers 7665 were classified as  
never smokers and 4365 as current smokers. The average  
time since smoking cessation for former smokers was 13  
years. The average cotinine level for current smokers was  
1255 nmol/l;for both former and never smokers the  
average cotinine level was <3nmol/l. 
                         Among the inflammatory risk factors,  
analysis of smoking status in a bivariate way showed that  
unadjusted C-reactive protein, fibrinogen and  
white blood cell count were all well increased. Smokers 
 also had higher total cholesterol antriglycerides.Prevalent  
 
 
 
85 
 
atherosclerotic cardiovascular disease was seen in former  
smokers. C-reactive protein had a co-relation with older  
age, female sex and black race. Similarly significant  
associations were observed in serum albumin and serum   
fibrinogen. 
                        The reduction of inflammatory response 
was observed  
 With reduction in the smoking intensity 
 
 Increased time since the person has stopped 
smoking 
 C-reactive protein and fibrinogen were higher with 
increased smoking  
intensity and were all negatively associated with time 
since the person quit  
smoking.The traditional cardiovascular risk factors such a 
s total and HDL  
cholesterol,triglycerides,alcohol usage and systolic blood 
pressure showed a  
dose-dependent association with smoking intensity. 
Among the inflammatory markers C-reactive protein 
continued to show  
reduction of acute phase reponse with a decrease in 
smoking intensity and  
increased time since cessation. 
Overall the following associations were made: 
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 Positive changes in both inflammatory markers 
and traditional risk factors  
with decreased intensity of smoking and 
 with increased time since cessation from smoking 
there is improvement in  
inflammatory markers. 
 
Discussion-It is known that after 5years of cessation from 
smoking the  
inflammatory changes reduces. With reduced exposure to 
tobacco vascular  
effects can be reversed and cardiovascular risk reduces  
gradually. 
These studies have examined inflammatory markers 
following  
smoking: the MONICA Study (Monitoring Trends and 
Determinants in  
cardiovascular Disease), Northwick Park Heart Study 
and the Cardiovascular  
Heart Study(CHS).The Northwick Park Heart study and 
MONICA study both  
found that fibrinogen levels reached normal levels within 
5years. 
Tobacco ranks the second important cause of preventable 
death in the world.It  
is also the fourth most common risk factor for disease. 
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Conclusion-Thus this study suggests that inflammatory 
problems 
of the cardiovascular disease that results from smoking is 
reversible with  
cessation of smoking. 
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MATERIALS AND 
METHODS 
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MATERIALS AND METHODS  
This study was conducted in our medical college hospital. 
Patients recruited from medicals wards and IMCU. A 
total of about 160 patients were selected and 10 of them 
were excluded as per exclusion criteria used. The 
remaining 150 patients were included in the 
study.Among them 100 patients are smokers and 50 are 
nonsmokers  Informed consent was obtained from all 
patients. Serum fibrinogen value was estimated in all 150 
patients admitted in our hospital. 
INCLUSION CRITERIA 
1. Patients and Relatives of outpatients and inpatients 
in tirunelveli medical  college. 
2. Healthy individuals between 20 to 60 years of age. 
EXCLUSION CITERIA  
1. Patients with history of diabetes mellitus 
2. Patients with history of hypertension 
3. Patients having hyperlipidemia 
4. Patients having vascular disorder, 
 
 
 
90 
 
5. Patients having  liver , kidney dysfunction 
6. Patients having thyroid dysfunction 
7. Patients having Infection,  
8. Patients taking aspirin or lipid lowering drugs  
9. Obese individuals 
10. Surgery in 3 months. 
11.  Patients  having space occupying lesions, 
12.  Subdural hematoma. 
 
METHODOLOGY 
For all the 150 cases admitted ,detailed clinical 
examination and history regarding smoking, alcohol, 
diabetes, hypertension, coronary heart disease, renal 
disease, any infection , surgery, trauma are enquired. 
Blood sugar ,ECG and routine investigation was done.  
Serum fibrinogen was measured in all these 150 patients 
who are included in the study and the values interpreted.   
SERUM FIBRINOGEN 
MEASUREMENT OF FIBRINOGEN7, 8 
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There are many fibrinogen assays available in various 
laboratory. Out of all the clauss method is the one that is 
most commonly used to determine serum fibrinogen 
value in most of the laboratories. Few of the tests are 
designed for an emergency situation where we need only 
to know whether the value is elevated or decreased. The 
exact fibrinogen value is not needed at certain times. 
 PREREQUISTE 
     WHO recommends tri-sodium citrate  to be used as an 
anticoagulant for determining serum fibrinogen value. 
The strength most commonly used is 0.105 to 0.109m.  
The sample to be used should contain 1 part of 
anticoagulant and 9 parts of blood. 
Under strict aseptic precautions the blood should be 
drawn rapidly  from the venepuncture site with minimal 
stasis and transferred to citrated container. 
This sample should be inverted gently to look for any 
clots. In the presence of clot or hemolysis the sample 
should not be used and discarded as this may interfere 
 
 
 
92 
 
with fibrinogen value. The blood sample collected can be 
stored 
at room temperature. 
PREPARATION OF SERUM:  
The sample collected should be subjected to centrifuge to 
remove the platelets . this centrifugation can be 
performed in room temperature. The resultant serum can 
be used immediately or stored in deep freeze at -70
0
C for 
maximum of 18 months. The photo optical methods used 
in determination of fibrinogen may interfere with the 
samples that are lipaemic or icteric and hence these 
samples should be avoided.  
 
FIBRINOGEN ASSAYS
9 
1. CLAUSS ASSAYS 
        It is the most commonly performed method to 
determine serum fibrinogen value. This test based on the 
rate of clot formation in dilute citrated serum following 
the addition of thrombin. The clotting of dilute serum is 
inversely proportional to the serum fibrinogen 
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concentration when high concentration of thrombin is 
used. In this procedure a high concentration of thrombin 
say 100μ/ml is added to platelet poor plasma and the 
clotting time is measured.  
        The high concentration of thrombin that is added to 
plasma ensures that wide fibrinogen values are 
independent of thrombin concentration. . The clotting end 
point is measured by either mechanical or photo-optical 
means, as these methods have shown excellent 
crosscorrelation and precision.  
The results are plotted in a calibration curve made from 
clotting times with serial dilution and fibrinogen 
concentration. The result obtained will be in mg/dl. 
   The most frequently used method is that of Von Clauss.. 
The amount of thrombin chosen ensures that the clotting 
time is dependant on the fibrinogen level of plasma 
sample. A high concentration of thrombin (ranging from 
35-200μ/ml, but typically about) is added to dilute test 
plasma and clotting time is measured, result is compared 
to a calibration curve prepared by clotting a series of 
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dilutions of a reference serum of known fibrinogen 
concentration and a result obtained is in mg/dl.  
. As this type of assay measures the time to formation of a 
detectable clot, the presence of inhibitors of fibrin 
polymerization, such as fibrinogen and14 fibrinogen 
degradation products results in under estimation of the 
actual fibrinogen concentration. 
 
     
PT  - BASED TESTS  
In this method prothrombin time is determined by optical 
density change in a platelet poor plasma and compared 
with derived fibrinogen in a calibration curve. 
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                   The other methods to determine fibrinogen include; 
1. Gravimetric method 
2. Immunological 
3. Salting out. 
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      OBSERVATION  AND  
               RESULTS 
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1.AGE DISTRIBUTION 
 
Age Cat 
  
Age 
Distribu
tion 
Perce
nt 
Valid 
Perce
nt 
Cumul
ative 
Percen
t 
Valid 20-29 35 23.3 23.3 23.3 
30-39 63 42.0 42.0 65.3 
40-49 49 32.7 32.7 98.0 
>50 3 2.0 2.0 100.0 
Total 150 100.0 100.0  
      
           
 
 
 
 
 
 
AGE(in years) 
 Smoker-1 
Nonsmoker-
0 
Mean 
Age N 
Std. 
Deviation 
 Non 
Smoker 
35.72 50 6.743 
 Smoker 36.92 100 7.770 
 Total 36.52 150 7.443 
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Smoker-1 
Nonsmoker-0 
Total 
 
  
Age 
Distribution 
Non 
Smoker Smoker 
 Age 
Cat 
20-29 11 24 35 
 30-39 24 39 63 
 40-49 15 34 49 
 >50 0 3 3 
 Total 50 100 150 
 
      
     
 
 
35.00 
35.50 
36.00 
36.50 
37.00 
Non Smoker Smoker 
Mean Age 
Mean Age 
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Persons in smoking criteria falls maximally inder the age  
group between 30 to 39 years of age.The mean age of  
smokers is 37. The mean age of non smokers is 36.  
Maximal number of persons in both smoking and non  
smoking criteria falls between 30 to 39 years of age. P  
value by chi square method is 0.501 and the symmetrical 
 measure value is 0.078. this proves that simply  
classifying the people according to age group is of no  
significance.  
 
 
 
0 
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15 
20 
25 
30 
35 
40 
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2.SMOKER VS NON-SMOKER 
 
 
 
 
 
 
 
 
 
 
The total numbers of smokers in my study is 100. 
 
The total number of non smokers in my study is 50. 
 
Smokers contributes 66.7% of my study. 
 
Non smokers contributes 33.3% of my study. 
 
 
 
 
 
 
 
 
Non smoker 
Smoker 
 
                                Smoker-1 Nonsmoker-0 
 
    Percent 
Valid 
Percent 
Cumulative 
Percent 
 Valid Non 
smoker 
50 33.3 33.3 33.3 
 Smoker 100 66.7 66.7 100.0 
 Total 150 100.0 100.0   
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3.TYPE OF SMOKING 
 
 
 
 
 
TYPE OF SMOKING Cig0bee1 
    
Type of 
Smoking Percent 
Valid 
Percent 
Cumulative 
Percent 
 Valid Cigarette 40 26.7 40.0 40.0 
 Beedi 60 40.0 60.0 100.0 
 Total 100 66.7 100.0   
 Missing System 50 33.3     
 Total 150 100.0     
 
      
                             
 
        
 
 
Type of Smoking 
Cigarette 
Beedi 
The total numbers of beedi smokers in my study is  
 
60. The total number of cigarette smoker is 40.  
 
Cigarette smoker contributes to 40% of the total  
 
150 persons. Beedi smokers contributes to 26.7%  
 
of total 150 persons. 
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4.PACKS PER DAY 
 
                                           
                                             packs cat 
    
No. of 
Packs 
per day Percent 
Valid 
Percent 
Cumulative 
Percent 
 Valid 1 to 2 32 21.3 32.0 32.0 
 3 to 4 46 30.7 46.0 78.0 
 >4 22 14.7 22.0 100.0 
 Total 100 66.7 100.0   
 Missing System 50 33.3     
 Total 150 100.0     
 
       
       Report 
 no of pkts 
 
Mean N 
Std. 
Deviation 
 3.26 100 1.440  
 
 
    
      
The maximal number of persons who smoke     
in my study smokes an average of 3 to 4 packs 
per day. The mean is 3.26 with a standard 
deviation of 1.440 
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          The majority of smokers in my study smokes 
 around 10 to 19 years. The mean value is 12.17   
     
0 
10 
20 
30 
40 
50 
<10 10 to 19 >=20 
Duration of smoking 
Duration of 
smoking 
 
5.DURATION OF SMOKING 
 
duration cat 
    
Duration 
of 
smoking Percent 
Valid 
Percent 
Cumulative 
Percent 
 Valid <10 39 26.0 39.0 39.0 
 10 to 19 49 32.7 49.0 88.0 
 >=20 12 8.0 12.0 100.0 
 Total 100 66.7 100.0   
 Missing System 50 33.3     
 Total 150 100.0     
 
       
       
       
 
 DURATION OF SMOKING 
 
Mean N 
Std. 
Deviation 
 12.17 100 6.171 
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with a standard deviation of 6.17 
 
6.PACK YEARS 
 
pack years cat 
 
    
Pack 
years Percent 
Valid 
Percent 
Cumulative 
Percent 
 Valid <40 54 36.0 54.0 54.0 
 40 to 80 35 23.3 35.0 89.0 
 80 to 
120 
10 6.7 10.0 99.0 
 >120 1 .7 1.0 100.0 
 Total 100 66.7 100.0   
 Missing System 50 33.3     
 Total 150 100.0     
 
       
        
 
 
                             
 
 
 
 
Maximal numer of smokers  54% in my study smokes 
 are having pack years of < 40 years. Only 1%  of the  
     
0 
10 
20 
30 
40 
50 
60 
<40 40 to 80 80 to 
120 
>120 
Pack years 
Pack years 
 
 
 
105 
 
                    smokers are  having a pack year of  > 120. 
 
 
Report 
  PACK YEARS 
  
Mean N Std. Deviation 
  41.74 100 28.873 
   
The mean pack years is 41.74 with a standard deviation of  
 
28.873   
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7.FIBRINOGEN 
 
 
Fibrin cat 
 
    
Fibrinogen 
levels Percent 
Valid 
Percent 
Cumulative 
Percent 
 Valid <450 50 33.3 33.3 33.3 
 450-475 28 18.7 18.7 52.0 
 475-500 38 25.3 25.3 77.3 
 500-525 24 16.0 16.0 93.3 
 >525 10 6.7 6.7 100.0 
 Total 150 100.0 100.0   
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Crosstab 
 Count 
 
    Smoker-1 Nonsmoker-0 
Total 
 
    Non Smokers Smokers 
 Fibrin cat <450 50 0 50 
 450-475 0 28 28 
 475-500 0 38 38 
 500-525 0 24 24 
 >525 0 10 10 
 Total 50 100 150 
 
       
 
All non smokers have serum fibrinogen value <450 mg%. 
 
 Where as majority of the smokers have a serum level of  
 
 Fibrinogen between 475 to 500 mg% 
 
 
 
 
Fibrin 
 Smoker-1 
Nonsmoker-
0 
Mean 
fibrinogen N 
Std. 
Deviation 
 Non 
Smokers 
311.92 50 37.101 
 Smokers 489.51 100 23.875 
     
 Total 430.31 150 88.808 
  
 
 
 
 
    
     
 
 
 
 
108 
 
 
 
 
 
 
 
 
 
 
     
 
  
  The mean serum fibrinogen value in non smokers is 318 mg%.  
 
The mean serum fibrinogen value in smokers is 489 mg.  
 
P value is < 0.01.  symmetrical measure is 0.706 which proves  
 
that the level of serum fibrinogen is smokers is significant and  
 
a positive correlation between smoking and  
 
the levels of fibrinogen. 
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8.PACKS VS FIBRINOGEN 
 
 
Count 
 
    packs cat 
Total 
 
    <3 3 to 4 >4 
 Fibrin cat 450-475 20 8 0 28 
 475-500 12 22 4 38 
 500-525 0 15 9 24 
 >525 0 1 9 10 
 Total 32 46 22 100 
 
       
 
Among the smoker who smoke less than 3 packs per day have serum 
fibrinogen levels  
between 450 to 475 mg%. Smokers  who smoke more than 4 packs per day 
have serum  
fibrinogen levels between 500 and 525 mg% with a statistical significance 
of p0.000 which  
clearly proves that a strong correlation exists between serum fibrinogen 
levels and the  
amount of smoking per day. 
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9.DURATION VS FIBRINOGEN 
 
 
Count 
 
    duration cat 
Total 
 
    <10 10 to 19 >20 
 Fibrin cat 450-475 27 1 0 28 
 475-500 11 24 3 38 
 500-525 1 18 5 24 
 >525 0 6 4 10 
 Total 39 49 12 100 
 
       
 
Among the smoker who have smoked less than 10 years have serum 
fibrinogen levels  
between 450 to 475 mg%. The persons who smoked > 10 years have serum  
fibrinogen levels  between 500 to 525mg% with a with a statistical 
significance of p0.000  
which clearly proves that a strong correlation exists between serum 
fibrinogen levels and  
the duration of smoking. 
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10.Fibrinogen and pack years: 
Count 
 
    pack years cat 
Total 
 
    <40 
40-
80 80-120 >120 
 Fibrin cat 450-475 28 0 0 0 28 
 475-500 26 12 0 0 38 
 500-525 0 23 1 0 24 
 >525 0 0 9 1 10 
 Total 54 35 10 1 100 
 
         
 
Among the smoker with pack years  less than 40 years have serum 
fibrinogen levels  
between 450 to 500 mg%. smoker with pack years  between 40 to 80 years 
have serum  
fibrinogen levels between 500 to 525 mg%. Smoker with pack years more 
than  
80 years have serum fibrinogen levels more than 525 mg%. 
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11.Type vs fibrinogen 
 
 
    
TYPE OF      
SMOKING 
Cig0bee1 
Total 
 
    Cigarette Beedi 
 Fibrin cat 450-475 23 5 28 
 475-500 14 24 38 
 500-525 2 22 24 
 >525 1 9 10 
 Total 40 60 100 
 
      
 
Among the smoker who have have serum fibrinogen levels  between 450 to 
475 mg%  most of them are cigarette smokers. Among the smoker who 
have have serum fibrinogen levels  between 475 to >525 mg% most of them 
are beedi smokers . this result has a statistical significance of p value0.000 
which proves that the result is significant 
 
 
 
. 
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12.REPORT 
 
 
 
 
 
 
 
 
Report 
  
TYPE OF      
SMOKING Cig0bee1 
 AGE(in 
years) 
no of 
pkts 
DURATION 
OF 
SMOKING 
PACK 
YEARS Fibrin CT 
  
aPTT(secs) 
  
CRP(mg/l) 
  Cigarette Mean 30.00 2.65 8.08 23.10 473.35 352.90 30.95 4.25 
  N 40 40 40 40 40 40 40 40 
  Std. 
Deviation 
4.315 1.442 4.178 19.052 18.137 36.986 .986 .954 
  Beedi Mean 41.53 3.67 14.90 54.17 500.28 296.48 29.75 5.52 
  N 60 60 60 60 60 60 60 60 
  Std. 
Deviation 
5.907 1.298 5.780 27.682 21.071 43.278 .968 1.127 
  Total Mean 36.92 3.26 12.17 41.74 489.51 319.05 30.23 5.01 
  N 100 100 100 100 100 100 100 100 
  Std. 
Deviation 
7.770 1.440 6.171 28.873 23.875 49.261 1.136 1.227 
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DISCUSSION 
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    DISCUSSION: 
This study is mainly done because the habit of smoking 
is very common in our culture. Almost every men living 
in my place had a  habit of smoking. They are also more 
prone for the adverse effects of smoking. Along with 
smoking  they are are also more prone for developing other 
habits like alcoholism and drug abuse. One of the main 
adverse  effect of smoking is  myocardial infarction. The 
main substance  present in smoking responsible for 
producing the adverse effect of smoking is nicotine. 
The main way by which smoking produces smoking is 
by inflammation. One of the main substance that is produced 
during inflammation is fibrinogen. It is mainly responsible 
for the  adverse effects of smoking like myocardial infarction , 
stroke and other  thrombotic episodes. Therefore this study 
is carried out to find out the levels of  serum fibrinogen 
in the smokers and to compare the levels of fibrinogen 
according to the type , duration and amount of smoking. 
The results of the study are interrupted here below. 
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TABLE 1 shows Persons in smoking criteria falls 
maximally inder the age  group between 30 to 39 years of 
age.The mean age of  smokers is 37. The mean age of non 
smokers is 36. Maximal number of persons in both smoking  
and non smoking criteria falls between 30 to 39 years of age.  
P value by chi square method is 0.501 and the symmetrical 
measure value is 0.078. this proves that simply 
classifying the people according to age group is of no 
significance. 
TABLE 2 shows The total numbers of smokers in my study is 
 
100. The total number of non smokers in my study is 50. 
 
Smokers contributes 66.7% of my study. 
 
Non smokers contributes 33.3% of my study. 
 
TABLE 3 shows The total numbers of beedi smokers in my study 
 
is  60. The total number of cigarette smoker is 40. 
 
Cigarette smoker contributes to 40% of the total 
 
150 persons. Beedi smokers contributes to 26.7% 
 
of total 150 persons. 
 
TABLE 4 shows  The maximal number of persons who smoke 
 
in my  study smokes an average of 3 to 4 packs per day. 
 
The mean is 3.26 with a  standard deviation of 1.440 
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TABLE 5  shows  The majority of smokers in my study 
smokes  around 10 to 19 years. The mean value is 
12.17  years with a standard deviation of 6.17. 
 
TABLE 6  shows   Maximal numer of smokers  54% in my 
study   are having pack years of < 40 years. Only 1%  of the 
smokers are  having a pack year of  > 120. 
The mean pack years is 41.74 with a standard deviation of 
 
28.873 
 
 
TABLE 7 Shows All non smokers have serum fibrinogen value 
 
<45  mg%. Where as majority of the smokers have a serum level of 
 
Fibrinogen between 475 to 500 mg% 
 
 
The mean serum fibrinogen value in non smokers is 318 mg%. 
 
The mean serum fibrinogen value in smokers is 489 mg. 
 
P value is < 0.01.  symmetrical measure is 0.706 which proves 
 
that the level of serum fibrinogen is smokers is significant and 
 
a positive correlation between smoking and 
 
the levels of fibrinogen 
. 
TABLE 8 shows Among the smoker who smoke less than 3 packs per 
day have serum fibrinogen levels  between 450 to 475 mg%. 
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Smokers  who smoke more than 4 packs per day 
have serum fibrinogen levels between 500 and 525 mg% with a 
statistical significance of p0.000 which clearly proves that 
a strong correlation exists between serum fibrinogen levels and the 
amount of smoking per day 
 
TABLE 9 shows  Among the smoker who have smoked less than 10 
years have serum fibrinogen levels between 450 to 475 mg%. 
The persons who smoked > 10 years have serum  fibrinogen levels 
between 500 to 525mg% with a with a statistical significance of p0.000 
which clearly proves that a strong correlation exists between serum 
fibrinogen levels and the duration of smoking 
 
TABLE 10 showsAmong the smoker with pack years  less than 
40 years have serum fibrinogen levels between 450 to 500 mg%. 
smoker with pack years  between 40 to 80 years have serum 
fibrinogen levels between 500 to 525 mg%. Smoker with pack years 
more than 80 years have serum fibrinogen levels more than 525 mg%. 
 
TABLE 11 shows Among the smoker who have have serum fibrinogen 
levels  between 450 to 475 mg%  most of them are cigarette smokers. 
 
Among the smoker who have have serum fibrinogen levels   
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between 475 to >525 mg% most of them are beedi smokers . 
 this result has a statistical significance of p value0.000  
which proves that the result is significant. 
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CONCLUSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
121 
 
 
 
 
 
 
 
 
Conclusion: 
1. Serum level of fibrinogen in smokers is significantly higher than in 
nonsmokers. 
2. Higher level of Smoking is associated with lower value of APTT. 
3. Higher level of smoking is associated with higher levels of CRP. 
4. Smokers who smoke more cigarettes or beedis per day have higher levels of 
serum fibrinogen. 
5. Smokers having higher pack years have higher levels of fibrinogen. 
6. Beedi smokers have higher levels of serum fibrinogen. 
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ANNEXURE 1 
 
A STUDY ON SERUM LEVELS OF FIBRINOGEN IN SMOKERS: 
 
PROFORMA: 
Date: 
Name: 
Age: 
Height: 
Weight: 
History of presenting illness: 
 
 
 
 
History of past illness: 
H/o  diabetes: 
H/o  hypertension: 
H/o  tuberculosis: 
H/o  CAHD: 
H/o  CVA: 
H/o  liver , kidney , thyroid disease: 
H/o DVT: 
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H/o drug intake: 
 
Personal history: 
Smoking: 
Type: 
Amount: 
Duration: 
 
Alcoholism: 
Drug abuse: 
 
General examination: 
 
Pulse: 
Bp: 
Respiratory rate: 
Temperature: 
CVS: 
RS: 
Abdomen: 
CNS: 
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Investigations: 
CBC: 
TC: 
DC: 
ESR: 
Hb: 
Platlets: 
Urea: 
Creatinine: 
Blood sugar: 
Lipid profile: 
CRP: 
Clotting time: 
APTT: 
Serum fibrinogen: 
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ANNEXURE 2: 
MASTER CHART OF CONTROL: 
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Master chart of cases
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ANNEXURE 3: 
KEY TO MASTER CHART: 
Types of smoking: 
0: Cigarette 
1: Beedi 
Pack years: Duration of smoking in years x no of packs of cigarettes / beedis 
per day. 
CRP: Normal value <1mg / dl. 
Clotting time: Normal value 120 to 360 seconds. 
APTT: Normal value 27 to 35 seconds 
Urea: Normal value in male 7 to 20 mg / dl. 
Creatinine: Normal value in males 0.6 to 1.2 mg /dl. 
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LDL cholesterol, mg/dL (mmol/L)    
  <70 (<1.81) Therapeutic option for very high risk patients 
  <100 (<2.59) Optimal 
  100–129 (2.59–3.34) Near optimal/above optimal 
  130–159 (3.36–4.11) Borderline high 
  160–189 (4.14–4.89) High 
  190 ( 4.91) 
Very high 
Total cholesterol, mg/dL (mmol/L)    
  <200 (<5.17) Desirable 
  200–239 (5.17–6.18) Borderline high 
  240 ( 6.21)  
High 
HDL cholesterol, mg/dL (mmol/L)    
  <40 (<1.03) Low 
  60 ( 1.55) 
High 
 
Serum fibrinogen: normal value 200 to 400 mg /dl. 
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ANNEXURE 4: 
ABBREVATIONS: 
CT: clotting time 
APTT: Activated Partial Thromboplastic Time 
CRP: C Reactive Protein 
TC: Total Count 
DC: Differential Count 
ESR: Erythrocyte Sedimentation Rate 
HB: Hemoglobin 
CAD: Coronary Artery Disease 
DVT: Deep Venous Thrombosis 
 
 
 
 
 
 
